Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021)
Scholar Rock Holding (SRRK) posted quarterly Current Deferred Revenue of $33.2 million for Q4 2021, up 76.41% year-over-year from $18.8 million in Q4 2020, and down 10.87% quarter-over-quarter from $37.2 million in Q3 2021.
Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $33.2 million for Q4 2021.
- In Q4 2021, Current Deferred Revenue rose 76.41% year-over-year to $33.2 million; the TTM figure through Dec 2021 stood at $33.2 million (up 76.41% YoY), while the FY2021 annual figure was $33.2 million, up 76.41% from the prior year.
- Current Deferred Revenue for Q4 2021 stood at $33.2 million, down from $37.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $47.3 million in Q1 2021, with the low at $228000.0 in Q4 2017.
- The 5-year median for Current Deferred Revenue is $20.6 million (2019), against an average of $24.5 million.
- The sharpest annual moves came in 2018 and 2020: Current Deferred Revenue jumped 8763.6% in 2018, then sank 35.84% in 2020.
- Scholar Rock Holding's Current Deferred Revenue stood at $228000.0 in 2017, then surged by 8763.6% to $20.2 million in 2018, then gained by 3.53% to $20.9 million in 2019, then dropped by 10.07% to $18.8 million in 2020, then surged by 76.41% to $33.2 million in 2021.
- Business Quant data shows SRRK's Current Deferred Revenue at $33.2 million in Q4 2021, $37.2 million in Q3 2021, and $42.7 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 33.19 Mn |
| Sep 30, 2021 | 37.24 Mn |
| Jun 30, 2021 | 42.71 Mn |
| Mar 31, 2021 | 47.30 Mn |
| Dec 31, 2020 | 18.82 Mn |
| Sep 30, 2020 | 16.71 Mn |
| Jun 30, 2020 | 20.36 Mn |
| Mar 31, 2020 | 16.27 Mn |
| Dec 31, 2019 | 20.92 Mn |
| Sep 30, 2019 | 20.25 Mn |
| Jun 30, 2019 | 23.52 Mn |
| Mar 31, 2019 | 25.36 Mn |
| Dec 31, 2018 | 20.21 Mn |
| Dec 31, 2017 | 228,000.00 |